Annual CFI
-$6.00 M
-$40.47 M-117.42%
31 December 2023
Summary:
Xeris Biopharma Holdings annual cash flow from investing activities is currently -$6.00 million, with the most recent change of -$40.47 million (-117.42%) on 31 December 2023. During the last 3 years, it has risen by +$21.40 million (+78.09%). XERS annual CFI is now -106.13% below its all-time high of $97.96 million, reached on 31 December 2021.XERS Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$9.91 M
+$5.31 M+115.38%
30 September 2024
Summary:
Xeris Biopharma Holdings quarterly cash flow from investing activities is currently $9.91 million, with the most recent change of +$5.31 million (+115.38%) on 30 September 2024. Over the past year, it has dropped by -$4.74 million (-32.35%). XERS quarterly CFI is now -72.91% below its all-time high of $36.60 million, reached on 31 December 2021.XERS Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$9.73 M
-$4.74 M-32.75%
30 September 2024
Summary:
Xeris Biopharma Holdings TTM cash flow from investing activities is currently $9.73 million, with the most recent change of -$4.74 million (-32.75%) on 30 September 2024. Over the past year, it has increased by +$21.44 million (+183.18%). XERS TTM CFI is now -90.06% below its all-time high of $97.96 million, reached on 31 December 2021.XERS TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XERS Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -117.4% | -32.4% | +183.2% |
| 3 y3 years | +78.1% | -46.4% | -85.8% |
| 5 y5 years | +91.2% | +497.2% | +292.2% |
XERS Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -106.1% | +78.1% | -72.9% | +122.5% | -90.1% | +149.5% |
| 5 y | 5 years | -106.1% | +91.2% | -72.9% | +116.3% | -90.1% | +122.3% |
| alltime | all time | -106.1% | +91.2% | -72.9% | +116.3% | -90.1% | +111.2% |
Xeris Biopharma Holdings Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $9.91 M(+115.4%) | $9.73 M(-32.8%) |
| June 2024 | - | $4.60 M(-123.4%) | $14.48 M(-21.0%) |
| Mar 2024 | - | -$19.65 M(-232.2%) | $18.32 M(-405.2%) |
| Dec 2023 | -$6.00 M(-117.4%) | $14.87 M(+1.5%) | -$6.00 M(-48.7%) |
| Sept 2023 | - | $14.65 M(+73.4%) | -$11.70 M(-40.4%) |
| June 2023 | - | $8.45 M(-119.2%) | -$19.65 M(+21.0%) |
| Mar 2023 | - | -$43.98 M(-579.7%) | -$16.23 M(-147.1%) |
| Dec 2022 | $34.46 M(-64.8%) | $9.17 M(+36.7%) | $34.46 M(-44.3%) |
| Sept 2022 | - | $6.71 M(-43.5%) | $61.90 M(-16.0%) |
| June 2022 | - | $11.87 M(+76.7%) | $73.69 M(-6.0%) |
| Mar 2022 | - | $6.72 M(-81.7%) | $78.38 M(-20.0%) |
| Dec 2021 | $97.96 M(-457.5%) | $36.60 M(+97.8%) | $97.96 M(+42.8%) |
| Sept 2021 | - | $18.50 M(+11.8%) | $68.61 M(-749.2%) |
| June 2021 | - | $16.56 M(-37.1%) | -$10.57 M(+8.1%) |
| Mar 2021 | - | $26.30 M(+262.8%) | -$9.78 M(-64.3%) |
| Dec 2020 | -$27.41 M | $7.25 M(-111.9%) | -$27.41 M(-37.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | -$60.67 M(-449.8%) | -$43.70 M(-401.7%) |
| June 2020 | - | $17.34 M(+99.9%) | $14.48 M(-42.1%) |
| Mar 2020 | - | $8.68 M(-196.0%) | $25.02 M(-1149.9%) |
| Dec 2019 | -$2.38 M(-96.5%) | -$9.04 M(+262.2%) | -$2.38 M(-53.0%) |
| Sept 2019 | - | -$2.50 M(-109.0%) | -$5.07 M(-91.4%) |
| June 2019 | - | $27.88 M(-248.9%) | -$58.62 M(-32.4%) |
| Mar 2019 | - | -$18.73 M(+59.7%) | -$86.65 M(+26.9%) |
| Dec 2018 | -$68.26 M(+9651.6%) | -$11.72 M(-79.1%) | -$68.26 M(+20.2%) |
| Sept 2018 | - | -$56.05 M(>+9900.0%) | -$56.77 M(+7469.9%) |
| June 2018 | - | -$156.00 K(-53.2%) | -$750.00 K(+8.5%) |
| Mar 2018 | - | -$333.00 K(+41.1%) | -$691.00 K(-1.3%) |
| Dec 2017 | -$700.00 K(+1900.0%) | -$236.00 K(+844.0%) | -$700.00 K(+50.9%) |
| Sept 2017 | - | -$25.00 K(-74.2%) | -$464.00 K(+5.7%) |
| June 2017 | - | -$97.00 K(-71.6%) | -$439.00 K(+28.4%) |
| Mar 2017 | - | -$342.00 K | -$342.00 K |
| Dec 2016 | -$35.00 K | - | - |
FAQ
- What is Xeris Biopharma Holdings annual cash flow from investing activities?
- What is the all time high annual CFI for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings annual CFI year-on-year change?
- What is Xeris Biopharma Holdings quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings quarterly CFI year-on-year change?
- What is Xeris Biopharma Holdings TTM cash flow from investing activities?
- What is the all time high TTM CFI for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings TTM CFI year-on-year change?
What is Xeris Biopharma Holdings annual cash flow from investing activities?
The current annual CFI of XERS is -$6.00 M
What is the all time high annual CFI for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high annual cash flow from investing activities is $97.96 M
What is Xeris Biopharma Holdings annual CFI year-on-year change?
Over the past year, XERS annual cash flow from investing activities has changed by -$40.47 M (-117.42%)
What is Xeris Biopharma Holdings quarterly cash flow from investing activities?
The current quarterly CFI of XERS is $9.91 M
What is the all time high quarterly CFI for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high quarterly cash flow from investing activities is $36.60 M
What is Xeris Biopharma Holdings quarterly CFI year-on-year change?
Over the past year, XERS quarterly cash flow from investing activities has changed by -$4.74 M (-32.35%)
What is Xeris Biopharma Holdings TTM cash flow from investing activities?
The current TTM CFI of XERS is $9.73 M
What is the all time high TTM CFI for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high TTM cash flow from investing activities is $97.96 M
What is Xeris Biopharma Holdings TTM CFI year-on-year change?
Over the past year, XERS TTM cash flow from investing activities has changed by +$21.44 M (+183.18%)